ArticleFrontiers in medicine2025
Application research on YOLOv5 model based on Lightweight Atrous Attention Module in brain tumor MRI image segmentation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To enhance the segmentation accuracy and computational efficiency of brain tumor magnetic resonance imaging (MRI) images, this study proposes a novel Lightweight Atrous Attention Module (LAAM) that integrates the Convolutional Block Attention Module (CBAM) with an Atrous Spatial Pyramid Pooling (ASPP) structure. The LAAM was integrated into the YOLOv5s model to enhance its performance, aiming to boost accuracy and recall while keeping computational efficiency. Methods: This study utilized two publicly available meningioma and glioma MRI datasets from Kaggle. The LAAM incorporates depthwise separable convolutions, dual attention mechanisms, and residual connections to reduce computational complexity while enhancing feature extraction capabilities. The modified YOLOv5s model was trained and validated via five-fold cross-validation, with performance comparisons conducted against the original YOLOv5s architecture and other optimized models. Results: The enhanced YOLOv5s-LAAM model demonstrated superior performance, achieving a precision of 92.3 %, a recall rate of 90.4 %, and an mAP@50 score of 0.925. Concurrently, the model exhibited significantly reduced computational demands, with the GFLOPs reduced by 15 % compared to the original YOLOv5s-ASPP baseline. Conclusion: The integration of the LAAM significantly enhances the YOLOv5s model's segmentation capabilities for brain tumor MRI images, making it a valuable tool for clinical diagnosis and treatment planning. The lightweight design ensures effective deployment in resource-constrained environments while maintaining high computational performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.